Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Protagonist Therapeutics Inc (PTGX): Adage Capital Management Reveals 9.69% Stake

Page 1 of 12

Phil Gross (pictured below) and Robert Atchinson‘s Adage Capital Management recently made a new addition to its portfolio, initiating a position in Protagonist Therapeutics Inc (NASDAQ:PTGX), which was revealed in a new 13G filing with the Securities and Exchange Commission. The fund has acquired 1.58 million common shares of the newly-public company, which represent 9.69% of its outstanding stock.

Protagonist Therapeutics is a clinical-stage biopharmaceutical company that just recently went public; the company is engaged in the development and production of peptide-based new chemical entities to help treat unresolved medical issues. Since the company started trading on August 12, its stock has gained 0.85%. There are no other known shareholders of the stock among the funds in our database at this time.

Phill Gross

Follow Protagonist Therapeutics Inc
Trade (PTGX) Now!

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Adage Capital Partners 0 1,581,076 0 1,581,076 1,581,076 9.69%
Adage Capital Partners GP 0 1,581,076 0 1,581,076 1,581,076 9.69%
Adage Capital Advisors 0 1,581,076 0 1,581,076 1,581,076 9.69%
Robert Atchinson 0 1,581,076 0 1,581,076 1,581,076 9.69%
Phillip Gross 0 1,581,076 0 1,581,076 1,581,076 9.69%

Phill Gross And Robert Atchinson
Phill Gross And Robert Atchinson
Adage Capital Management

Page 1 of 12 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*

Protagonist
Therapeutics, Inc.

(Name of Issuer)

Common Stock,
$0.00001 par value per share

(Title of Class of Securities)

74366E102

(CUSIP Number)

August 11,
2016

(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
(Page 1 of 12 Pages)

______________________________

*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act“) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).

Page 1 of 12

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!